Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
On June 11, 2018, Neuralstem, Inc. (“Company”) held its 2018 Annual Meeting (“Annual Meeting”) at 9:30 a.m. EDT at 20271 Goldenrod Lane, Suite 2059, Germantown, MD 20876. Only stockholders of record as of the close of business on April 24, 2018 (“Record Date”) were entitled to vote at the Annual Meeting. As of the Record Date, 15,160,014 shares of the Company’s common stock were issued, outstanding and entitled, of which 10,502,236 shares were represented, in person or by proxy, and which constituted a quorum. The final results of the stockholder vote on each proposal brought before the meeting were as follows:
(a) Proposal 1. The following individuals were elected as the Class I Directors to serve for a three-year term expiring at the 2021 Annual Meeting based upon the following votes:
| Broker | |||
| Nominee | Votes For | Votes Withheld | Non-Votes |
| Scott Ogilvie | 1,635,135 | 271,609 | 8,595,492 |
| Sandford Smith | 1,487,044 | 419,700 | 8,595,492 |
(b) Proposal 2. The ratification of Dixon Hughes Goodman, the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 was ratified based upon the following votes:
| Broker | |||
| Votes For | Votes Against | Abstentions | Non-Votes |
| 9,743,284 | 88,229 | 669,723 | — |
About Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.
